BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 21834681)

  • 1. The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo.
    Oliveira MN; Hemerly JP; Bastos AU; Tamanaha R; Latini FR; Camacho CP; Impellizzeri A; Maciel RM; Cerutti JM
    Thyroid; 2011 Sep; 21(9):975-85. PubMed ID: 21834681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple endocrine neoplasia type 2A due to an exon 8 (G533C) mutation in a large North American kindred.
    Castro MR; Thomas BC; Richards ML; Zhang J; Morris JC
    Thyroid; 2013 Dec; 23(12):1547-52. PubMed ID: 23461807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel de novo germ-line V292M mutation in the extracellular region of RET in a patient with phaeochromocytoma and medullary thyroid carcinoma: functional characterization.
    Castellone MD; Verrienti A; Magendra Rao D; Sponziello M; Fabbro D; Muthu M; Durante C; Maranghi M; Damante G; Pizzolitto S; Costante G; Russo D; Santoro M; Filetti S
    Clin Endocrinol (Oxf); 2010 Oct; 73(4):529-34. PubMed ID: 20039896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 6-Base Pair in Frame Germline Deletion in Exon 7 Of RET Leads to Increased RET Phosphorylation, ERK Activation, and MEN2A.
    Latteyer S; Klein-Hitpass L; Khandanpour C; Zwanziger D; Poeppel TD; Schmid KW; Führer D; Moeller LC
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1016-22. PubMed ID: 26765577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene.
    Toledo RA; Wagner SM; Coutinho FL; Lourenço DM; Azevedo JA; Longuini VC; Reis MT; Siqueira SA; Lucon AM; Tavares MR; Fragoso MC; Pereira AA; Dahia PL; Mulligan LM; Toledo SP
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1318-27. PubMed ID: 20080836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
    Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
    Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene.
    Peppa M; Boutati E; Kamakari S; Pikounis V; Peros G; Panayiotides IG; Economopoulos T; Raptis SA; Hadjidakis D
    Eur J Endocrinol; 2008 Dec; 159(6):767-71. PubMed ID: 18805915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of RET polymorphisms in a six-generation family with G533C RET mutation: specific RET variants may modulate age at onset and clinical presentation.
    Tamanaha R; Camacho CP; Pereira AC; da Silva AM; Maciel RM; Cerutti JM
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):56-64. PubMed ID: 19138318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.
    Machens A; Dralle H
    Mol Cell Endocrinol; 2006 Mar; 247(1-2):34-40. PubMed ID: 16343738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
    Gujral TS; Mulligan LM
    Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of RET gene should be performed in patients with multiple endocrine neoplasia type 2 (MEN 2) syndrome and no apparent genotype-phenotype correlation: an appraisal of p.Y791F and p.C634Y RET mutations in five unrelated Brazilian families.
    Valente FO; Dias da Silva MR; Camacho CP; Kunii IS; Bastos AU; da Fonseca CC; Simião HP; Tamanaha R; Maciel RM; Cerutti JM
    J Endocrinol Invest; 2013 Dec; 36(11):975-81. PubMed ID: 23723040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical patterns and RET proto-oncogene in fifteen multiple endocrine neoplasia type 2A pedigrees].
    Zhou YL; Zhu SX; Li JJ; Liu JB; Yin M; Xiao BY; Yu CL; Wang LM; Gu LQ; Cui B; Ning G; Li XY; Zhao YJ
    Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):466-70. PubMed ID: 17663821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family].
    Benazzouz B; Hafidi A; Benkhira S; Chraibi A; Kadiri A; Hilal L
    Bull Cancer; 2008 Apr; 95(4):457-63. PubMed ID: 18495576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.
    Milos IN; Frank-Raue K; Wohllk N; Maia AL; Pusiol E; Patocs A; Robledo M; Biarnes J; Barontini M; Links TP; de Groot JW; Dvorakova S; Peczkowska M; Rybicki LA; Sullivan M; Raue F; Zosin I; Eng C; Neumann HP
    Endocr Relat Cancer; 2008 Dec; 15(4):1035-41. PubMed ID: 18794325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.
    Jimenez C; Habra MA; Huang SC; El-Naggar A; Shapiro SE; Evans DB; Cote G; Gagel RF
    J Clin Endocrinol Metab; 2004 Aug; 89(8):4142-5. PubMed ID: 15292360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations.
    de Groot JW; Plaza Menacho I; Schepers H; Drenth-Diephuis LJ; Osinga J; Plukker JT; Links TP; Eggen BJ; Hofstra RM
    Surgery; 2006 Jun; 139(6):806-14. PubMed ID: 16782438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.
    Mise N; Drosten M; Racek T; Tannapfel A; Pützer BM
    Oncogene; 2006 Oct; 25(50):6637-47. PubMed ID: 16715139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple endocrine neoplasia type 2A: case report.
    Păun DL; Poiană C; Petriş R; Radian S; Miulescu RD; Constantinescu G; Orban C
    Chirurgia (Bucur); 2013; 108(6):900-3. PubMed ID: 24331334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.